PT - JOURNAL ARTICLE AU - Erin M. Jonaitis AU - Shorena Janelidze AU - Karly A. Cody AU - Rebecca Langhough Koscik AU - Lianlian Du AU - Nathaniel A. Chin AU - Niklas Mattsson-Carlgren AU - Kirk J. Hogan AU - Bradley T. Christian AU - Tobey J. Betthauser AU - Oskar Hansson AU - Sterling C. Johnson TI - Plasma pTau-217 in preclinical Alzheimer’s disease AID - 10.1101/2022.06.09.22276206 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.09.22276206 4099 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276206.short 4100 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276206.full AB - Background and Objectives An accurate blood test for Alzheimer’s disease (AD) that is sensitive to preclinical proteinopathy and cognitive decline has clear implications for early detection and secondary prevention of AD. We assessed the performance of plasma pTau against brain PET markers of amyloid ([11C]-PiB) and tau ([18F]MK-6240), and its utility for predicting longitudinal cognition.Methods Samples were analyzed from a subset of participants with up to 8 years follow-up in the Wisconsin Registry for Alzheimer’s Prevention (WRAP; 2001-present; plasma 2011-present), a longitudinal cohort study of adults from midlife, enriched for parental history of AD. Participants were a convenience sample who volunteered for at least one PiB scan, had usable banked plasma, and were cognitively unimpaired at first plasma collection. Study personnel who interacted with participants or samples were blind to amyloid status. We used mixed effects models and receiver-operator characteristic curves to assess concordance between plasma pTau217 and PET biomarkers of AD, and mixed effects models to understand the ability of plasma pTau217 to predict longitudinal performance on WRAP’s preclinical Alzheimer’s cognitive composite (PACC-3).Results The primary analysis included 165 people (108 women; mean age=62.9 ± 6.06; 160 still enrolled; 2 deceased; 3 discontinued). Plasma pTau217 was strongly related to PET-based estimates of concurrent brain amyloid (β̂DVR = 0.83 (0.75, 0.90), p<.001). Concordance was high between plasma pTau217 and both amyloid PET (AUC=0.91, specificity=0.80, sensitivity=0.85, PPV=0.58, NPV=0.94, LR−=5.48) and tau PET (AUC=0.95, specificity=1, sensitivity=0.85, PPV=1, NPV=0.98, LR−=6.47). Higher baseline pTau217 levels were associated with worse cognitive trajectories (β̂pTau=age = -0.07 (-0.09, -0.06), p<.001).Conclusions and Relevance In a convenience sample of unimpaired adults, plasma pTau217 levels correlate well with concurrent brain AD pathophysiology and with prospective cognitive performance. These data indicate that this marker can detect AD before clinical signs and thus may disambiguate presymptomatic AD from normal cognitive aging.Classification of Evidence This study meets Class III evidential criteria for diagnostic accuracy of plasma pTau217.Competing Interest StatementOH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. SCJ has served as a consultant to Eisai and Roche Diagnostics, has received an equipment grant from Roche Diagnostics, and has received support (sponsoring of an observational study and provision of precursor for tau imaging) from Cerveau Technologies. Authors EMJ, SJ, KAC, RLK, LD, NAC, NMC, KJH, BTC, and TJB have nothing to disclose. Work at the University of Wisconsin was supported by NIH R01AG027161 (Johnson), NIH RO1AG021155 (Johnson), AARF 19614533 (Betthauser), S10 OD025245-01 (Christian) and the University of Wisconsin Institute for Clinical and Translational Research NIH UL1TR002375 (Cody). We extend our deepest thanks to the WRAP participants and staff for their invaluable contributions to the study. Work at Lund University was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Sk&aringne University Hospital Foundation (2020-O000028), Regionalt Forskningsst&oumld (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279).Funding StatementOH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. SCJ has served as a consultant to Eisai and Roche Diagnostics, has received an equipment grant from Roche Diagnostics, and has received support (sponsoring of an observational study and provision of precursor for tau imaging) from Cerveau Technologies. Authors EMJ, SJ, KAC, RLK, LD, NAC, NMC, KJH, BTC, and TJB have nothing to disclose. Work at the University of Wisconsin was supported by NIH R01AG027161 (Johnson), NIH RO1AG021155 (Johnson), AARF 19614533 (Betthauser), S10 OD025245-01 (Christian) and the University of Wisconsin Institute for Clinical and Translational Research NIH UL1TR002375 (Cody). We extend our deepest thanks to the WRAP participants and staff for their invaluable contributions to the study. Work at Lund University was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Sk&aringne University Hospital Foundation (2020-O000028), Regionalt Forskningsst&oumld (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health Sciences IRB of University of Wisconsin-Madison gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.